GlassScriptPhysician profile
Alisha Maity
NPI 1013544600
$5,263.20
in general payments reported to CMS, 2019-2025
39 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $722 · 2024: $2,287 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,624 · Education: $599 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,624.09 |
| Education | $598.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.79 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $524.95 | 2024-2025 | |
| Astellas Pharma US INC | $426.99 | 2023-2025 | Xospata, Xtandi, Vyloy |
| Seagen INC. | $335.79 | 2023-2025 | Tukysa |
| Alexion Pharmaceuticals, INC. | $266.78 | 2024-2025 | Ultomiris |
| Janssen Biotech, INC. | $264.29 | 2024-2025 | Carvykti, Erleada, Rybrevant |
| Pfizer INC. | $233.65 | 2023-2025 | |
| Daiichi Sankyo INC. | $230.31 | 2024-2025 | Enhertu |
| Genentech USA, INC. | $172.00 | 2023-2025 | Venclexta |
| Boston Scientific Corporation | $164.43 | 2025 | Therasphere Administration Set |
| Genzyme Corporation | $143.62 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $133.92 | 2025 | |
| Galvanize Therapeutics, INC | $133.83 | 2025 | Aliya System |
| Ipsen Biopharmaceuticals, INC | $129.59 | 2024-2025 | Onivyde, Somatuline Depot |
| Tempus Ai, INC | $123.42 | 2024-2025 | Xt Cdx |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $119.18 | 2023-2025 | Opdivo |
| Lilly USA, LLC | $117.00 | 2023-2024 | Verzenio |
| Eisai INC. | $97.88 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.98 | 2023-2025 | Ninlaro |
| Merck Sharp & Dohme LLC | $54.50 | 2025 | Lynparza, Keytruda |
| Puma Biotechnology, INC. | $50.55 | 2024-2025 | |
| Pharmaessentia USA Corporation | $49.28 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $44.12 | 2024-2025 | |
| Abbvie INC. | $42.30 | 2023-2025 | |
| Acrotech Biopharma INC. | $40.18 | 2024 | Beleodaq |
| Cumberland Pharmaceuticals, INC. | $33.73 | 2023-2024 | Sancuso |
| Mirati Therapeutics, INC. | $33.73 | 2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $33.05 | 2025 | Libtayo |
| Caris Mpi, INC. | $31.49 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $29.77 | 2024-2025 | Ojjaara |
| Incyte Corporation | $29.25 | 2025 | Jakafi |
| Tersera Therapeutics LLC | $26.53 | 2024 | Quzyttir |
| Apellis Pharmaceuticals, INC. | $23.09 | 2024 | Empaveli |
| Sobi, INC | $22.43 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.39 | 2024 | Xarelto |
| Amgen INC. | $18.74 | 2023 | Vectibix, Nplate, Xgeva |
| Novocure INC. | $16.77 | 2025 | Optune Lua (Novottf-200t) |
| Emd Serono, INC. | $16.45 | 2025 | |
| Deciphera Pharmaceuticals INC. | $14.45 | 2023 | Qinlock |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Maity listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.